Cost effectiveness and strategic planning (WHO-CHOICE)

EUR B: Cost effectiveness results for Tuberculosis

This Table provides summary results of the total population-level costs, effects and cost-effectiveness for the selected WHO sub-region and risk factor / disease for the year 2000.

KEY
I$ - International Dollars
Program Costs include costs of administration, media, training etc
Patient Costs include costs of hospital visits, drugs, etc
Incremental cost-effectiveness ratio (ICER) is defined as the incremental change in cost, divided by the incremental change in effectiveness. ICERs are reported for the successive set of interventions that would be selected at expanding levels of resource availability, starting with the intervention with the lowest cost per DALY averted, then moving to the next most cost-effective combination intervention out of the remaining available set of interventions.
Dominated is used to denote an intervention that is more costly and/or less effective than other, more efficient (single or combined) interventions; i.e. dominated interventions do not appear on the expansion path of most cost-effective strategies.


Interventions:Codes_and_Descriptions Coverage Cost per year (I$, millions) per one million_population [i.e. cost per capita] % Program costs % Patient costs DALYs averted per year per one million_population Average Cost per DALY averted Incremental Cost per DALY averted
TB-1: SmearPos: Treatment of new smear-positive cases only under DOTS 50% 0.63 77% 23% 38,782 16 16
TB-2: SmearPosNeg: As for SmearPos, plus treatment of smear-negative cases under DOTS 50% 0.70 73% 27% 40,403 17 Dominated
TB-3: SmearPosMDR: As for SmearPos, plus DOTS-plus treatment 50% 0.90 57% 43% 39,140 23 Dominated
TB-4: Combination: As SmearPos, plus DOTS treatment of smear-negative cases plus DOTS-plus standardized second-line drug re-treatment 50% 0.96 56% 44% 40,721 24 Dominated
TB-5: SmearPos: Treatment of new smear-positive cases only under DOTS 80% 1.02 78% 22% 62,051 16 17
TB-6: SmearPosNeg: As for SmearPos, plus treatment of smear-negative cases under DOTS 80% 1.13 73% 27% 64,645 17 Dominated
TB-7: SmearPosMDR: As for SmearPos, plus DOTS-plus treatment 80% 1.45 57% 43% 62,623 23 Dominated
TB-8: Combination: As SmearPos, plus DOTS treatment of smear-negative cases plus DOTS-plus standardized second-line drug re-treatment 80% 1.55 56% 44% 65,153 24 Dominated
TB-9: SmearPos: Treatment of new smear-positive cases only under DOTS 95% 1.40 81% 19% 73,686 19 33
TB-10: SmearPosNeg: As for SmearPos, plus treatment of smear-negative cases under DOTS 95% 1.58 77% 23% 76,766 21 58
TB-11: SmearPosMDR: As for SmearPos, plus DOTS-plus treatment 95% 1.96 63% 37% 74,365 26 Dominated
TB-12: Combination: As SmearPos, plus DOTS treatment of smear-negative cases plus DOTS-plus standardized second-line drug re-treatment 95% 2.12 62% 38% 77,370 27 909
Share